{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:58:42Z","timestamp":1791536322824,"version":"4.3.4"},"reference-count":74,"publisher":"Archives of Endocrinology and Metabolism","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,16]]},"DOI":"10.20945\/2359-3997000000556","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T15:26:20Z","timestamp":1668698780000},"page":"666-677","source":"Crossref","is-referenced-by-count":54,"title":["Normocalcemic primary hyperparathyroidism"],"prefix":"10.20945","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-5336","authenticated-orcid":false,"given":"Natalie E.","family":"Cusano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-9547","authenticated-orcid":false,"given":"Filomena","family":"Cetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"10","key":"key20221117102615_B1","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1210\/jc.2014-1415","article-title":"Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the fourth International Workshop","volume":"99","author":"Silverberg","year":"2014","unstructured":"Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3580-94.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20221117102615_B2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/jc.2008-1760","article-title":"Presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop","volume":"94","author":"Silverberg","year":"2009","unstructured":"Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94(2):351-65.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20221117102615_B3","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1210\/jc.2014-1414","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the fourth international workshop","volume":"99","author":"Eastell","year":"2014","unstructured":"Eastell R, Brandi ML, Costa AG, D\u2019Amour P, Shoback DM, Thakker R V. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the fourth international workshop. J Clin Endocrinol Metab. 2014;99(10):3570-9.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20221117102615_B4","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop","volume":"99","author":"Bilezikian","year":"2014","unstructured":"Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. J Clin Endocrinol Metab. 2014;99(10):3561-9.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20221117102615_B5","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021)","volume":"186","author":"Bollerslev","year":"2022","unstructured":"Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L, et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). Eur J Endocrinol. 2022;186(2):R33-63.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"key20221117102615_B6","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1210\/jc.2013-1300","article-title":"Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations","volume":"98","author":"Cusano","year":"2013","unstructured":"Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab. 2013;98(7):2734-41.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10-11","key":"key20221117102615_B7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.clinbiochem.2011.04.002","article-title":"Biochemical diagnosis of primary hyperparathyroidism: Analysis of the sensitivity of total and ionized calcium in combination with PTH","volume":"44","author":"Nordenstr\u00f6m","year":"2011","unstructured":"Nordenstr\u00f6m E, Katzman P, Bergenfelz A. Biochemical diagnosis of primary hyperparathyroidism: Analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem. 2011;44(10\u201311):849-52.","journal-title":"Clin Biochem"},{"issue":"9","key":"key20221117102615_B8","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1210\/jc.2012-1429","article-title":"The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism","volume":"97","author":"Ong","year":"2012","unstructured":"Ong GSY, Walsh JP, Stuckey BGA, Brown SJ, Rossi E, Ng JL, et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97(9):3138-45.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20221117102615_B9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know","volume":"96","author":"Ross","year":"2011","unstructured":"Ross AC, Manson JAE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20221117102615_B10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0272-6386(97)90330-9","article-title":"The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure","volume":"29","author":"Martinez","year":"1997","unstructured":"Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29(4):496-502.","journal-title":"Am J Kidney Dis"},{"key":"key20221117102615_B11","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"113","author":"Group KDIGO (KDIGO) C-MW","year":"2009","unstructured":"Group KDIGO (KDIGO) C-MW. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-130.","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"key20221117102615_B12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","unstructured":"Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99(2):144-52.","journal-title":"Am J Med"},{"issue":"10","key":"key20221117102615_B13","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1111\/bcp.13332","article-title":"Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study","volume":"83","author":"Cipriani","year":"2017","unstructured":"Cipriani C, Pepe J, Clementelli C, Manai R, Colangelo L, Fassino V, et al. Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study. Br J Clin Pharmacol. 2017;83(10):2266-73.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"key20221117102615_B14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-31.","journal-title":"N Engl J Med"},{"issue":"9","key":"key20221117102615_B15","first-page":"2844","article-title":"Alterations in parathyroid dynamics in lithium-treated subjects","volume":"82","author":"Haden","year":"1997","unstructured":"Haden ST, Stoll AL, Mccormick S, Scott J, Fuleihan GEH. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab. 1997;82(9):2844-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20221117102615_B16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2796.2001.00868.x","article-title":"Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: A randomized controlled study","volume":"250","author":"Rejnmark","year":"2001","unstructured":"Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: A randomized controlled study. J Intern Med. 2001;250(2):144-53.","journal-title":"J Intern Med"},{"issue":"2","key":"key20221117102615_B17","doi-asserted-by":"crossref","first-page":"L27","DOI":"10.1210\/jc.2014-4065","article-title":"Letter to the Editor: Thiazides Are Not Inducers of PTH Secretion: A Comment on Normocalcemic Hyperparathyroidism","volume":"100","author":"Yacobi-Bach","year":"2015","unstructured":"Yacobi-Bach M, Serebro M, Greenman Y, Tordjman K, Stern N. Letter to the Editor: Thiazides Are Not Inducers of PTH Secretion: A Comment on Normocalcemic Hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(2):L27.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20221117102615_B18","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/jgs.13661","article-title":"Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults","volume":"63","author":"Hinson","year":"2015","unstructured":"Hinson AM, Wilkerson BM, Rothman-Fitts I, Riggs AT, Stack BC, Bodenner DL. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc. 2015;63(10):2070-3.","journal-title":"J Am Geriatr Soc"},{"key":"key20221117102615_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01517","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk","volume":"9","author":"Ye","year":"2019","unstructured":"Ye Y, Zhao C, Liang J, Yang Y, Yu M, Qu X. Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk. Front Pharmacol. 2019;9:1-9.","journal-title":"Front Pharmacol"},{"issue":"4","key":"key20221117102615_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12040929","article-title":"25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and peripheral bone densitometry in adults with celiac disease","volume":"12","author":"Ciacci","year":"2020","unstructured":"Ciacci C, Bilancio G, Russo I, Iovino P, Cavallo P, Santonicola A, et al. 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and peripheral bone densitometry in adults with celiac disease. Nutrients. 2020;12(4):1-11.","journal-title":"Nutrients"},{"issue":"10","key":"key20221117102615_B21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/BF03346429","article-title":"Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion","volume":"31","author":"Balsa","year":"2008","unstructured":"Balsa JA, Botella-Carretero JI, Peromingo R, Zamarr\u00f3n I, Arrieta F, Mu\u00f1oz-Malo T, et al. Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Invest. 2008;31(10):845-50.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"key20221117102615_B22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI107156","article-title":"Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria","volume":"52","author":"Coe","year":"1973","unstructured":"Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest. 1973;52(1):134-42.","journal-title":"J Clin Invest"},{"issue":"1","key":"key20221117102615_B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12399-9","article-title":"Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion","volume":"10","author":"Centeno","year":"2019","unstructured":"Centeno PP, Herberger A, Mun HC, Tu C, Nemeth EF, Chang W, et al. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun. 2019;10(1):1-12.","journal-title":"Nat Commun"},{"issue":"6","key":"key20221117102615_B24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/cen.12732","article-title":"Normocalcaemic hypoparathyroidism: Prevalence and effect on bone status in older women. The OPUS study","volume":"82","author":"Palermo","year":"2015","unstructured":"Palermo A, Jacques R, Gossiel F, Reid DM, Roux C, Felsenberg D, et al. Normocalcaemic hypoparathyroidism: Prevalence and effect on bone status in older women. The OPUS study. Clin Endocrinol (Oxf). 2015;82(6):816-23.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"key20221117102615_B25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1590\/S0004-27302011000500003","article-title":"Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?","volume":"55","author":"Marques","year":"2011","unstructured":"Marques TF, Vasconcelos R, Diniz E, R\u00eago D, Griz L, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol. 2011;55(5):314-7.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"4","key":"key20221117102615_B26","doi-asserted-by":"crossref","first-page":"E1171","DOI":"10.1210\/clinem\/dgaa084","article-title":"Normocalcemic hyperparathyroidism: Study of its prevalence and natural history","volume":"105","author":"Schini","year":"2020","unstructured":"Schini M, Jacques RM, Oakes E, Peel NFA, Walsh JS, Eastell R. Normocalcemic hyperparathyroidism: Study of its prevalence and natural history. J Clin Endocrinol Metab. 2020;105(4):E1171-86.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20221117102615_B27","article-title":"Normocalcaemic Primary Hyperparathyroidism: Is nephrolithiasis more common than osteoporosis?","author":"Wu","year":"2021","unstructured":"Wu K, Anpalahan M. Normocalcaemic Primary Hyperparathyroidism: Is nephrolithiasis more common than osteoporosis? Intern Med J. 2021.","journal-title":"Intern Med J"},{"issue":"3","key":"key20221117102615_B28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1530\/EC-15-0030","article-title":"Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy","volume":"4","author":"Vignali","year":"2015","unstructured":"Vignali E, Cetani F, Chiavistelli S, Meola A, Saponaro F, Centoni R, et al. Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy. Endocr Connect. 2015;4(3):172-8.","journal-title":"Endocr Connect"},{"issue":"3","key":"key20221117102615_B29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0039-6060(97)90357-3","article-title":"Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women","volume":"121","author":"Lundgren","year":"1997","unstructured":"Lundgren E, Rastad J, Thurfjell E, \u00c5kerstr\u00f6m G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997;121(3):287-94.","journal-title":"Surgery"},{"issue":"4","key":"key20221117102615_B30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/a-0859-1020","article-title":"Normocalcemic Primary Hyperparathyroidism in Adults Without a History of Nephrolithiasis or Fractures: A Prospective Study","volume":"51","author":"Ros\u00e1rio","year":"2019","unstructured":"Ros\u00e1rio PW, Calsolari MR. Normocalcemic Primary Hyperparathyroidism in Adults Without a History of Nephrolithiasis or Fractures: A Prospective Study. Horm Metab Res. 2019;51(4):243-7.","journal-title":"Horm Metab Res"},{"issue":"2","key":"key20221117102615_B31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cen.12819","article-title":"Normocalcaemic, vitamin D-sufficient hyperparathyroidism - High prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden","volume":"83","author":"Kontogeorgos","year":"2015","unstructured":"Kontogeorgos G, Trimpou P, Laine CM, Oler\u00f6d G, Lindahl A, Landin-Wilhelmsen K. Normocalcaemic, vitamin D-sufficient hyperparathyroidism - High prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol (Oxf). 2015;83(2):277-84.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"key20221117102615_B32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cen.12569","article-title":"Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers","volume":"82","author":"Berger","year":"2015","unstructured":"Berger C, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse RG, et al. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf). 2015;82(3):359-68.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"key20221117102615_B33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12020-012-9694-z","article-title":"Normocalcemic primary hyperparathyroidism: One-year follow-up in one hundred postmenopausal women","volume":"42","author":"Garc\u00eda-Mart\u00edn","year":"2012","unstructured":"Garc\u00eda-Mart\u00edn A, Reyes-Garc\u00eda R, Mu\u00f1oz-Torres M. Normocalcemic primary hyperparathyroidism: One-year follow-up in one hundred postmenopausal women. Endocrine. 2012;42(3):764-6.","journal-title":"Endocrine"},{"issue":"4","key":"key20221117102615_B34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00268-012-1438-y","article-title":"Surgical management of normocalcemic primary hyperparathyroidism","volume":"36","author":"Wade","year":"2012","unstructured":"Wade TJ, Yen TWF, Amin AL, Wang TS. Surgical management of normocalcemic primary hyperparathyroidism. World J Surg. 2012;36(4):761-6.","journal-title":"World J Surg"},{"issue":"3","key":"key20221117102615_B35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4158\/EP15704.OR","article-title":"Primary Hyperparathyroidism, With a Focus on Management of the Normocalcemic Form: To Treat or Not To Treat?","volume":"22","author":"\u0160iprov\u00e1","year":"2016","unstructured":"\u0160iprov\u00e1 H, Fry\u0161\u00e1k Z, Sou\u010dek M. Primary Hyperparathyroidism, With a Focus on Management of the Normocalcemic Form: To Treat or Not To Treat? Endocr Pract. 2016;22(3):294-301.","journal-title":"Endocr Pract"},{"issue":"7","key":"key20221117102615_B36","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa174","article-title":"Clinical, biochemical and radiological profile of normocalcemic primary hyperparathyroidism","volume":"105","author":"Palermo","year":"2020","unstructured":"Palermo A, Naciu AM, Tabacco G, Falcone S, Santonati A, Maggi D, et al. Clinical, biochemical and radiological profile of normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2020;105(7).","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key20221117102615_B37","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1210\/jc.2006-2802","article-title":"Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype","volume":"92","author":"Lowe","year":"2007","unstructured":"Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8):3001-5.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20221117102615_B38","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic Primary Hyperparathyroidism: Evidence for a Generalized Target-Tissue Resistance to Parathyroid Hormone","volume":"88","author":"Maruani","year":"2003","unstructured":"Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic Primary Hyperparathyroidism: Evidence for a Generalized Target-Tissue Resistance to Parathyroid Hormone. J Clin Endocrinol Metab. 2003;88(10):4641-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key20221117102615_B39","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.amjmed.2004.06.037","article-title":"Characterization of normocalcemic primary hyperparathyroidism","volume":"117","author":"Tordjman","year":"2004","unstructured":"Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004;117(11):861-3.","journal-title":"Am J Med"},{"key":"key20221117102615_B40","first-page":"2012","article-title":"Normocalcemic versus hypercalcemic primary hyperparathyroidism: More stone than bone?","author":"Amaral","year":"2012","unstructured":"Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: More stone than bone? J Osteoporos. 2012;2012.","journal-title":"J Osteoporos"},{"issue":"2","key":"key20221117102615_B41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12020-012-9627-x","article-title":"Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism","volume":"42","author":"Cakir","year":"2012","unstructured":"Cakir I, Unluhizarci K, Tanriverdi F, Elbuken G, Karaca Z, Kelestimur F. Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine. 2012;42(2):419-22.","journal-title":"Endocrine"},{"issue":"1","key":"key20221117102615_B42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02173","article-title":"Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening","volume":"155","author":"Hagstr\u00f6m","year":"2006","unstructured":"Hagstr\u00f6m E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33-9.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"key20221117102615_B43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4158\/EP14195.OR","article-title":"Normocalcemic hyperparathyroidism and insulin resistance","volume":"21","author":"Temizkan","year":"2015","unstructured":"Temizkan S, Kocak O, Aydin K, Ozderya A, Arslan G, Yucel N, et al. Normocalcemic hyperparathyroidism and insulin resistance. Endocr Pract. 2015;21(1):23-9.","journal-title":"Endocr Pract"},{"issue":"2","key":"key20221117102615_B44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1507\/endocrj.EJ15-0392","article-title":"Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients","volume":"63","author":"Ozturk","year":"2016","unstructured":"Ozturk FY, Erol S, Canat MM, Karatas S, Kuzu I, Cakir SD, et al. Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J. 2016;63(2):111-8.","journal-title":"Endocr J"},{"issue":"6","key":"key20221117102615_B45","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1210\/jc.2014-4432","article-title":"Is normocalcemic primary hyperparathyroidism harmful or harmless?","volume":"100","author":"Chen","year":"2015","unstructured":"Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, et al. Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab. 2015;100(6):2420-4.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20221117102615_B46","doi-asserted-by":"crossref","first-page":"107985","DOI":"10.1016\/j.diabres.2019.107985","article-title":"Increased parathyroid hormone is associated with higher fasting glucose in individuals with normocalcemic primary hyperparathyroidism and prediabetes: A pilot study","volume":"160","author":"Karras","year":"2020","unstructured":"Karras SN, Koufakis T, Tsekmekidou X, Antonopoulou V, Zebekakis P, Kotsa K. Increased parathyroid hormone is associated with higher fasting glucose in individuals with normocalcemic primary hyperparathyroidism and prediabetes: A pilot study. Diabetes Res Clin Pract. 2020;160:107985.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"key20221117102615_B47","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1530\/EJE-09-1067","article-title":"Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"162","author":"Tordjman","year":"2010","unstructured":"Tordjman KM, Yaron M, Izkhakov E, Osher E, Shenkerman G, Marcus-Perlman Y, et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol. 2010;162(5):925-33.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"key20221117102615_B48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4158\/EP-2020-0405","article-title":"Echocardiographic Findings in Patients With Normocalcemic Primary Hyperparathyroidism Compared With Findings in Hypercalcemic Primary Hyperparathyroid Patients and Control Subjects","volume":"27","author":"Pepe","year":"2021","unstructured":"Pepe J, Colangelo L, Sonato C, Occhiuto M, Ferrara C, Del Fattore A, et al. Echocardiographic Findings in Patients With Normocalcemic Primary Hyperparathyroidism Compared With Findings in Hypercalcemic Primary Hyperparathyroid Patients and Control Subjects. Endocr Pract. 2021;27(1):21-6.","journal-title":"Endocr Pract"},{"issue":"1","key":"key20221117102615_B49","first-page":"149","article-title":"Coronary artery disease is more severe in patients with primary hyperparathyroidism","volume":"167","author":"Koubaity","year":"2020","unstructured":"Koubaity O, Mandry D, Nguyen-Thi PL, Bihain F, Nomine-Criqui C, Demarquet L, et al. Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surg (United States). 2020;167(1):149-54.","journal-title":"Surg (United States)"},{"key":"key20221117102615_B50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/VHRM.S128084","article-title":"Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism","volume":"13","author":"Mesquita","year":"2017","unstructured":"Mesquita PN, Leite APDL, Cris\u00f3stomo S das C, Filho EV, Da Cunha Xavier L, Bandeira F. Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism. Vasc Health Risk Manag. 2017;13:225-9.","journal-title":"Vasc Health Risk Manag"},{"key":"key20221117102615_B51","doi-asserted-by":"crossref","first-page":"115583","DOI":"10.1016\/j.bone.2020.115583","article-title":"Impaired physical function and evaluation of quality of life in normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"141","author":"Voss","year":"2020","unstructured":"Voss L, N\u00f3brega M, Bandeira L, Griz L, Rocha-Filho PAS, Bandeira F. Impaired physical function and evaluation of quality of life in normocalcemic and hypercalcemic primary hyperparathyroidism. Bone. 2020;141:115583.","journal-title":"Bone"},{"issue":"4","key":"key20221117102615_B52","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2015","unstructured":"Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, et al. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int. 2015;26(4):1295-302.","journal-title":"Osteoporos Int"},{"issue":"1","key":"key20221117102615_B53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4081\/aiua.2015.1.66","article-title":"Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study","volume":"87","author":"Brardi","year":"2015","unstructured":"Brardi S, Cevenini G, Verdacchi T, Romano G, Ponchietti R. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Arch Ital Urol Androl. 2015;87(1):66-71.","journal-title":"Arch Ital Urol Androl"},{"issue":"12","key":"key20221117102615_B54","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1210\/jc.2012-2272","article-title":"Calcium Associations with Incident Cardiovascular Disease and Mortality: The MIDSPAN Family Study","volume":"97","author":"Welsh","year":"2012","unstructured":"Welsh P, Doolin O, Mcconnachie A, Boulton E, Mcneil G, Macdonald H, et al. Calcium Associations with Incident Cardiovascular Disease and Mortality: The MIDSPAN Family Study. J Clin Endocrinol Metab. 2012;97(12):4578-87.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20221117102615_B55","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","article-title":"The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism","volume":"151","author":"Wilhelm","year":"2016","unstructured":"Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, et al. The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016;151(10):959-68.","journal-title":"JAMA Surg"},{"key":"key20221117102615_B56","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/B978-0-12-397166-1.00035-7","volume-title":"The Parathyroids: Basic and Clinical Concepts","author":"Mariani","year":"2015","unstructured":"Mariani G, Mazzeo S, Rubello B. Preoperative localization of abnormal parathyroid glands. In: Bilezikian J, Marcus R, Levine M, Marcocci C, Silverberg S, Potts JJ, editors. The Parathyroids: Basic and Clinical Concepts. 3rd ed. San Diego: Elsevier; 2015. p. 499-515.","edition":"3rd ed."},{"issue":"6","key":"key20221117102615_B57","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cen.14667","article-title":"Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT\/CT results compare with hypercalcemic hyperparathyroidism","volume":"96","author":"Musumeci","year":"2022","unstructured":"Musumeci M, Pereira LV, San Miguel L, Cianciarelli C, Vazquez EC, Mollerach AM, et al. Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT\/CT results compare with hypercalcemic hyperparathyroidism. Clin Endocrinol (Oxf). 2022;96(6):831-6.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"key20221117102615_B58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40618-018-0931-z","article-title":"PETC\/CT with 18 F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism","volume":"42","author":"Bossert","year":"2019","unstructured":"Bossert I, Chytiris S, Hodolic M, Croce L, Mansi L, Chiovato L, et al. PETC\/CT with 18 F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. J Endocrinol Invest. 2019;42(4):419-26.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"key20221117102615_B59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjsurg.2019.10.032","article-title":"Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form?","volume":"219","author":"G\u00f3mez-Ram\u00edrez","year":"2020","unstructured":"G\u00f3mez-Ram\u00edrez J, G\u00f3mez-Valdazo A, Luengo P, Porrero B, Osorio I, Rivas S. Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? Am J Surg. 2020;219(1):150-3.","journal-title":"Am J Surg"},{"issue":"4","key":"key20221117102615_B60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/1754-9485.12728","article-title":"Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism","volume":"62","author":"Cunha-Bezerra","year":"2018","unstructured":"Cunha-Bezerra P, Vieira R, Amaral F, Cartaxo H, Lima T, Montarroyos U, et al. Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism. J Med Imaging Radiat Oncol. 2018;62(4):493-8.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"2","key":"key20221117102615_B61","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1148\/radiol.2019182122","article-title":"Diagnostic performance of 4D CT and sestamibi SPECT\/CT in localizing parathyroid adenomas in primary hyperparathyroidism","volume":"291","author":"Yeh","year":"2019","unstructured":"Yeh R, Tay YKD, Tabacco G, Dercle L, Kuo JH, Bandeira L, et al. Diagnostic performance of 4D CT and sestamibi SPECT\/CT in localizing parathyroid adenomas in primary hyperparathyroidism. Radiology. 2019;291(2):469-76.","journal-title":"Radiology"},{"issue":"1","key":"key20221117102615_B62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3174\/ajnr.A3615","article-title":"4D-CT for preoperative localization of abnormal parathyroid glands in patients with hyperparathyroidism: Accuracy and ability to stratify patients by unilateral versus bilateral disease in surgery-na\u00efve and re-exploration patients","volume":"35","author":"Kelly","year":"2014","unstructured":"Kelly HR, Hamberg LM, Hunter GJ. 4D-CT for preoperative localization of abnormal parathyroid glands in patients with hyperparathyroidism: Accuracy and ability to stratify patients by unilateral versus bilateral disease in surgery-na\u00efve and re-exploration patients. Am J Neuroradiol. 2014;35(1):176-81.","journal-title":"Am J Neuroradiol"},{"issue":"6","key":"key20221117102615_B63","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.surg.2006.07.028","article-title":"Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography","volume":"140","author":"Rodgers","year":"2006","unstructured":"Rodgers SE, Hunter GJ, Hamberg LM, Schellingerhout D, Doherty DB, Ayers GD, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery. 2006;140(6):932-41.","journal-title":"Surgery"},{"issue":"2","key":"key20221117102615_B64","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1245\/s10434-018-6998-0","article-title":"Biochemical and Skeletal Outcomes of Parathyroidectomy for Normocalcemic (Incipient) Primary Hyperparathyroidism","volume":"26","author":"Sho","year":"2019","unstructured":"Sho S, Kuo EJ, Chen AC, Li N, Yeh MW, Livhits MJ. Biochemical and Skeletal Outcomes of Parathyroidectomy for Normocalcemic (Incipient) Primary Hyperparathyroidism. Ann Surg Oncol. 2019;26(2):539-46.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"key20221117102615_B65","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.surg.2019.06.043","article-title":"Normocalcemic hyperparathyroidism: A Collaborative Endocrine Surgery Quality Improvement Program analysis","volume":"167","author":"Pandian","year":"2020","unstructured":"Pandian TK, Lubitz CC, Bird SH, Kuo LE, Stephen AE. Normocalcemic hyperparathyroidism: A Collaborative Endocrine Surgery Quality Improvement Program analysis. Surgery. 2020;167(1):168-72.","journal-title":"Surgery"},{"issue":"1","key":"key20221117102615_B66","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.surg.2018.04.065","article-title":"Bone mineral density changes after parathyroidectomy are dependent on biochemical profile","volume":"165","author":"Lee","year":"2019","unstructured":"Lee D, Walker MD, Chen HY, Chabot JA, Lee JA, Kuo JH. Bone mineral density changes after parathyroidectomy are dependent on biochemical profile. Surgery. 2019;165(1):107-13.","journal-title":"Surgery"},{"issue":"3","key":"key20221117102615_B67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00423-018-1659-0","article-title":"Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?","volume":"403","author":"Traini","year":"2018","unstructured":"Traini E, Bellantone R, Tempera SE, Russo S, De Crea C, Lombardi CP, et al. Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism? Langenbeck's Arch Surg. 2018;403(3):317-23.","journal-title":"Langenbeck's Arch Surg"},{"issue":"4","key":"key20221117102615_B68","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/0194599818793879","article-title":"Surgical Management of Normocalcemic Primary Hyperparathyroidism and the Impact of Intraoperative Parathyroid Hormone Testing on Outcome","volume":"159","author":"Trinh","year":"2018","unstructured":"Trinh G, Rettig E, Noureldine SI, Russell JO, Agrawal N, Mathur A, et al. Surgical Management of Normocalcemic Primary Hyperparathyroidism and the Impact of Intraoperative Parathyroid Hormone Testing on Outcome. Otolaryngol Head Neck Surg. 2018;159(4):630-7.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"key20221117102615_B69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/bjs.10739","article-title":"Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism","volume":"105","author":"Bannani","year":"2018","unstructured":"Bannani S, Christou N, Gu\u00e9rin C, Hamy A, Sebag F, Mathonnet M, et al. Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. Br J Surg. 2018;105(3):223-9.","journal-title":"Br J Surg"},{"issue":"8","key":"key20221117102615_B70","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/jc.2013-1518","article-title":"Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism","volume":"98","author":"Koumakis","year":"2013","unstructured":"Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98(8):3213-20.","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"key20221117102615_B71","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1245\/s10434-013-3190-4","article-title":"Multigland disease and slower decline in intraoperative PTH characterize mild primary hyperparathyroidism","volume":"20","author":"Schneider","year":"2013","unstructured":"Schneider DF, Burke JF, Ojomo KA, Clark N, Mazeh H, Sippel RS, et al. Multigland disease and slower decline in intraoperative PTH characterize mild primary hyperparathyroidism. Ann Surg Oncol. 2013;20(13):4205-11.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"key20221117102615_B72","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00268-019-05157-x","article-title":"Biochemical Profile Affects IOPTH Kinetics and Cure Rate in Primary Hyperparathyroidism","volume":"44","author":"Graves","year":"2020","unstructured":"Graves CE, McManus CM, Chabot JA, Lee JA, Kuo JH. Biochemical Profile Affects IOPTH Kinetics and Cure Rate in Primary Hyperparathyroidism. World J Surg. 2020;44(2):488-95.","journal-title":"World J Surg"},{"issue":"1","key":"key20221117102615_B73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-019-1093-4","article-title":"Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"19","author":"Beysel","year":"2019","unstructured":"Beysel S, Caliskan M, Kizilgul M, Apaydin M, Kan S, Ozbek M, et al. Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc Disord. 2019;19(1):1-8.","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"key20221117102615_B74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12113522","article-title":"Improving glucose homeostasis after parathyroidectomy for normocalcemic primary hyperparathyroidism with co-existing prediabetes","volume":"12","author":"Karras","year":"2020","unstructured":"Karras S, Kotsa K, Annweiler C, Kiortsis D, Koutelidakis I. Improving glucose homeostasis after parathyroidectomy for normocalcemic primary hyperparathyroidism with co-existing prediabetes. Nutrients. 2020;12(11):1-9.","journal-title":"Nutrients"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T15:27:10Z","timestamp":1668698830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/normocalcemic-primary-hyperparathyroidism-2\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11,16]]}},"alternative-id":["10.20945\/2359-3997000000556"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000556","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}